121 Seaport Blvd Boston
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Company Ownership: Public
Stock Symbol: AZN
Stock Exchange: Nasdaq
715 articles with Alexion
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
1/13/2020The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Apellis Pharmaceuticals announced that its pegcetacoplan beat out Alexion Pharmaceuticals’ Soliris in its Phase III PEGASUS study in adults with paroxysmal nocturnal hemoglobinuria.
Alexion Pharmaceuticals announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14th, 2019 at 7:30 a.m, PT. A breakout question and answer session will immediately follow the formal presentation.
Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.
Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC™ RNAi molecules.
Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team
Shares of Alexion Pharmaceuticals have jumped nearly 5% after the company’s board of directors rejected a push for a sale of the company from one of its largest stakeholders, U.K.-based Elliott Advisors, Ltd.
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.
Alexion Pharmaceuticals announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five scientific data presentations from the company’s complement program will be showcased during the annual meeting of the American Society of Hematology (ASH) in Orlando, Fla., from Dec. 7 to 10, 2019.
Alexion Pharmaceuticals, Inc. announced financial results for the third quarter of 2019.
Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response
Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for Factor D inhibition in additional alternative pathway complement-mediated rare diseases
The deal is expected to close in the first half of 2020.
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the company’s first Chief Corporate Affairs Officer
Following the release of the financial results, Alexion management will conduct a conference call and audio webcast at 8:00 a.m. Eastern Time